| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $3.18B | +10.6% |
| Cost of Revenue | $384.4M | +24.1% |
| Gross Profit | $2.80B | +9.0% |
| R&D Expense | $550.0M | +14.3% |
| SG&A Expense | $755.8M | +6.5% |
| Operating Income | $1.49B | +8.4% |
| Pre-tax Income | $1.71B | +11.4% |
| Income Tax | $379.2M | +10.3% |
| Net Income | $1.33B |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.56B | -8.3% |
| Short-term Investments | $1.36B | -13.2% |
| Accounts Receivable | $350.2M | +25.4% |
| Inventory | $183.1M | +16.0% |
| Current Assets | $3.70B | -4.4% |
| Total Assets | $7.88B | +7.0% |
| Current Liabilities | $560.6M | -24.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.56B | +17.6% |
| Capital Expenditures | $520.5M | +111.2% |
| Investing Cash Flow | -$551.3M | -232.1% |
| Financing Cash Flow | -$1.15B | +8.4% |
| Free Cash Flow | $1.04B | -3.7% |
| +11.7% |
| EPS (Basic) | $30.13 | +14.0% |
| EPS (Diluted) | $27.86 | +13.1% |
| Total Liabilities |
| $783.8M |
| -14.8% |
| Stockholders' Equity | $7.10B | +10.1% |